SCHEMBL4809775

SCHEMBL4809775

OC[C@H]1S[C@@H](Oc2ccc(Cl)cc2Cc2ccc(Cl)cc2Cl)[C@H](O)[C@@H](O)[C@@H]1O

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC5A2 P31639 12/20 0.38
SLC5A1 P13866 11/20 0.38
CYP1A2 P05177 4/20 0.35
CYP2C9 P11712 4/20 0.35
PTGER1 P34995 3/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2C19 P33261 2/20 0.35
MAPK1 P28482 1/20 0.35
IDO1 P14902 1/20 0.33
ALDH1A1 P00352 1/20 0.33
TBXA2R P21731 1/20 0.33
PTGFR P43088 1/20 0.33
PTGER3 P43115 1/20 0.33
PTGER2 P43116 1/20 0.33
PTGIR P43119 1/20 0.33
PTGDR Q13258 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4809778 1.00 SLC5A2 (0.38) SLC5A2SLC5A1CYP1A2CYP2C9PTGER1
SCHEMBL4815023 0.86 PTGER1 (0.41) SLC5A2SLC5A1CYP1A2CYP2C9PTGER1
SCHEMBL4815015 0.86 PTGER1 (0.41) SLC5A2SLC5A1CYP1A2CYP2C9PTGER1
SCHEMBL4811060 0.84 SLC5A2 (0.42) SLC5A2SLC5A1ALDH1A1
SCHEMBL4811056 0.84 SLC5A2 (0.42) SLC5A2SLC5A1ALDH1A1
SCHEMBL4817702 0.84 PTGER1 (0.40) SLC5A2SLC5A1CYP1A2CYP2C9PTGER1
SCHEMBL4817695 0.84 PTGER1 (0.40) SLC5A2SLC5A1CYP1A2CYP2C9PTGER1
SCHEMBL14080145 0.84 SLC5A2 (0.45) SLC5A2SLC5A1PTGER1CYP3A4
SCHEMBL4805370 0.84 SLC5A1 (0.40) SLC5A2SLC5A1
SCHEMBL4805362 0.84 SLC5A1 (0.40) SLC5A2SLC5A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7414072-B2 Aryl 5-thio-β-d-glucopyranoside derivatives and therapeutic agents for diabetes containing the same TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-08-19 US disclosed
US-7414072-B2 Aryl 5-thio-β-d-glucopyranoside derivatives and therapeutic agents for diabetes containing the same TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-08-19 US disclosed
US-7414072-B2 Aryl 5-thio-β-d-glucopyranoside derivatives and therapeutic agents for diabetes containing the same TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-08-19 US disclosed
US-20050209309-A1 Aryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same TAISHO PHARMACEUTICAL CO., LTD. 2005-09-22 US disclosed
EP-1528066-A1 ARYL 5-THIO-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME TAISHO PHARMACEUTICAL CO., LTD (JP) 2005-05-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209309-A1 Aryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same SLC5A2, SLC5A1, UGGT1 SLC5A2 1/4885SLC5A1 2/4885CYP1A2 610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.